Teijin Limited Signs Joint R&D Agreement with Garwood Medical Devices

Following a press release from Garwood Medical Devices, WKBW and others have reported that the Buffalo-based medtech company and leading Japanese conglomerate Teijin Limited announced a joint research and development agreement to bring Garwood Medical’s novel infection control technology to Japan.

Garwood Medical is developing BioPrax™, a treatment for preventing and treating infections associated with metallic implants, such as those used for knees and hips, which is a serious unmet need for patients.

BioPrax was built from technology exclusively licensed to Garwood Medical from the University at Buffalo and Syracuse University, and with strong support from UB, including subsidized R&D funding, specialized lab space and more. Garwood Medical is currently conducting pre-clinical studies and plans to start clinical trials in late 2024.

The investment and agreement with Teijin Limited—a $9 billion technology-driven global group with two core businesses: high-performance materials and healthcare solutions—is a substantial milestone in Garwood Medical's commercialization efforts.

Teijin has committed significant funds through Pegasus Tech Ventures, a global venture capital firm based in Silicon Valley. In addition to the investment, Teijin and Garwood will undergo joint R&D efforts in Japan with the objective of developing products for the Japanese market.

Read the full press release, or watch coverage.